The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer
Open accessAbstract
Expression of matrix metalloproteinase 9 (MMP9) is elevated in a variety of inflammatory and oncology indications, including ulcerative colitis and colorectal cancer. MMP9 is a downstream effector and an upstream mediator of pathways involved in growth and inflammation, and has long been viewed as a promising therapeutic target. However, previous efforts to target matrix metalloproteinases (MMPs), including MMP9, have utilized broad-spectrum or semi-selective inhibitors. While some of these drugs showed signs of efficacy in patients, all MMP-targeted inhibitors have been hampered by dose-limiting toxicity or insufficient clinical benefit, likely due to their lack of specificity. Here, we show that selective inhibition of MMP9 did not induce musculoskeletal syndrome (a characteristic toxicity of pan-MMP inhibitors) in a rat model, but did reduce disease severity in a dextran sodium sulfate-induced mouse model of ulcerative colitis. We also found that MMP9 inhibition decreased tumor growth and metastases incidence in a surgical orthotopic xenograft model of colorectal carcinoma, and that inhibition of either tumor- or stroma-derived MMP9 was sufficient to reduce primary tumor growth. Collectively, these data suggest that selective MMP9 inhibition is a promising therapeutic strategy for treatment of inflammatory and oncology indications in which MMP9 is upregulated and is associated with disease pathology, such as ulcerative colitis and colorectal cancer. In addition, we report the development of a potent and highly selective allosteric MMP9 inhibitor, the humanized monoclonal antibody GS-5745, which can be used to evaluate the therapeutic potential of MMP9 inhibition in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 1×
“The observed difference in anti-metastases efficacy is consistent with evidence supporting a prominent role for stromal MMP9 in metastatic growth [65, 70, 73, 96, 97].”
ResultYu, Q., & Stamenkovic, I. (2000) · Genes & Development · doi:10.1101/gad.14.2.163 · Cited by 1,754
Strategies for MMP inhibition in cancer: innovations for the post-trial era
Overall, C. M., & López-Otín, C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc884 · Cited by 1,349
Gelatinase B functions as regulator and effector in leukocyte biology
Opdenakker, G., Van den Steen, P. E., Dubois, B., Nelissen, I., Van Coillie, E., Masure, S., Proost, P., & Van Damme, J. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.69.6.851 · Cited by 553 · cited 1×
“Since neutrophil degranulation releases MMP9 without the typical co-secretion of endogenous inhibitor TIMP1 [110], these cells can deliver a large amount of cleavage-competent enzyme directly at the disease site.”
Background
Cited by
Current and emerging therapeutic targets for IBD
Neurath, M. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.208 · Cited by 691
Neutrophils as emerging therapeutic targets
Németh, T., Sperandio, M., & Mócsai, A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0054-z · Cited by 653
Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview
Mondal, S., Adhikari, N., Banerjee, S., Amin, S. A., & Jha, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112260 · Cited by 556
de Almeida, L. G. N., Thode, H., Eslambolchi, Y., Chopra, S., Young, D., Gill, S., Devel, L., & Dufour, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000349 · Cited by 535
Matrix Metalloproteinases as Therapeutic Targets for Idiopathic Pulmonary Fibrosis
Craig, V. J., Zhang, L., Hagood, J. S., & Owen, C. A. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0020tr · Cited by 507
Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment
Liu, T., Zhou, L., Li, D., Andl, T., & Zhang, Y. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00060 · Cited by 446
“In a pre-clinical study, an anti-MMP9 monoclonal antibody GS-5745 successfully inhibited tumor growth and reduced tumor metastasis in mice bearing colorectal tumors (Marshall et al., 2015).”
BackgroundThe Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review
Ma, W.-T., Gao, F., Gu, K., & Chen, D.-K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01140 · Cited by 361
Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics
Raeeszadeh-Sarmazdeh, M., Do, L., & Hritz, B. (2020) · Cells · doi:10.3390/cells9051313 · Cited by 324
The Dual Role of Neutrophils in Inflammatory Bowel Diseases
Wéra, O., Lancellotti, P., & Oury, C. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5120118 · Cited by 316
The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma
Fields, G. B. (2019) · Cells · doi:10.3390/cells8090984 · Cited by 299
Webb, A. H., Gao, B. T., Goldsmith, Z. K., Irvine, A. S., Saleh, N., Lee, R. P., Lendermon, J. B., Bheemreddy, R., Zhang, Q., Brennan, R. C., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3418-y · Cited by 275
Matrix metalloproteinases as regulators of inflammatory processes
Fingleton, B. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.05.010 · Cited by 261
MMP9: A Tough Target for Targeted Therapy for Cancer
Augoff, K., Hryniewicz-Jankowska, A., Tabola, R., & Stach, K. (2022) · Cancers · doi:10.3390/cancers14071847 · Cited by 255
Zhu, L., Tang, Y., Li, X.-Y., Keller, E. T., Yang, J., Cho, J.-S., Feinberg, T. Y., & Weiss, S. J. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw6143 · Cited by 178
“In the case of anti-human MMP9 antibodies, phase 2 clinical trials indicate that the drug is well tolerated (81).”
Background
Metadata
- Authors
- Marshall, D. C., Lyman, S. K., McCauley, S., Kovalenko, M., Spangler, R., Liu, C., Lee, M., O’Sullivan, C., Barry-Hamilton, V., Ghermazien, H., Mikels-Vigdal, A., Garcia, C. A., Jorgensen, B., Velayo, A. C., Wang, R., Adamkewicz, J. I., & Smith, V.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-05-11
- Volume
- 10
- Issue
- 5
- Pages
- e0127063
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1428077152
- Cited by
- 201
- References
- 6
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.